Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors

• US 7,132,415 B2
• Filed: 09/19/2002
• Issued: 11/07/2006
• Est. Priority Date: 09/21/2001
• Status: Expired due to Fees

• Current Assignee: Merck Sharp & Dohme Corporation (Merck & Co., Inc.)
• Original Assignee: Schering Corporation (Merck & Co., Inc.)
• Inventors: Davis, Harry R.
• Primary Examiner(s): KIM, VICKIE Y
• Application Number:
  US10/247,095
• Publication Number:
  US 20030119809A1
• Time in Patent Office: 1,510 Days
• Field of Search: 424/94.1, 514/210.02, 514/210, 514/23
• US Class Current: 514/210.02
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/397 having four-membered rings, e.g. azetidine
• CPC Class Codes: A61K 31/7052 having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

The present invention provides therapeutic combinations and methods including at least one sterol or 5α-stanol absorption inhibitor that can be useful for treating xanthomas.

Claims

1. A method of decreasing the incidence of xanthoma in a subject comprising the step of administering to a subject in need of such treatment an effective amount of a combination of (i) at least one sterol absorption inhibitor, at least one 5α

-stanol absorption inhibitor, or a pharmaceutically acceptable salt or solvate thereof and (ii) at least one HMG-CoA reductase inhibitor as a cholesterol biosynthesis inhibitor, to decrease the incidence of xanthoma in the subject, wherein the at least one sterol or 5α

-stanol absorption inhibitor is represented by Formula (I);

2. The method according to claim 1, wherein the HMG-CoA reductase inhibitor is selected from the group consisting of pravastatin, lovastatin, simvastatin, fluvastatin, rivastatin, rosuvastatin, atorvastatin, cerivastatin, and combinations thereof.